Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FS-1502 in HER2-positive advanced solid tumors
CTR20220135Phase 2Completed
- Sponsor
- Fosun Pharma
- Start
- Jan 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of caxmotabart entudotin in transitional cell carcinoma (TCC), biliary cancer, pancreatic cancer (PC), ovarian cancer, endometrial cancer (EC), sponsored by Fosun Pharma. Started Jan 2022; status: completed.
02
Drugs
caxmotabart entudotin
03
Conditions
transitional cell carcinoma (TCC)biliary cancerpancreatic cancer (PC)ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on CTR20220135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220135.